Sale!

Anti NMO Neuromyelitis Optica Panel CSF Test Cost

Original price was: 1,700 د.إ.Current price is: 1,200 د.إ.

-29%

The Anti NMO (Neuromyelitis Optica) Panel CSF Test is a specialized diagnostic procedure designed to detect the presence of antibodies associated with Neuromyelitis Optica Spectrum Disorder (NMOSD) in the cerebrospinal fluid (CSF). NMOSD is a rare, autoimmune disorder of the central nervous system that primarily affects the optic nerves and spinal cord, leading to vision loss, muscle weakness, and paralysis.

This test is crucial for the accurate diagnosis and differentiation of NMOSD from other similar conditions like multiple sclerosis (MS), as the treatment and management strategies for these conditions can significantly differ. Identifying the presence of specific antibodies, such as aquaporin-4 (AQP4) antibodies, helps in confirming the diagnosis of NMOSD and facilitates the initiation of appropriate treatment protocols.

Performed at DNA Labs UAE, a reputable facility known for its advanced diagnostic services, the Anti NMO Neuromyelitis Optica Panel CSF Test ensures high accuracy and reliability. The test is priced at 1200 AED, reflecting the specialized nature of the procedure and the sophisticated technology employed in conducting the analysis. For individuals presenting with symptoms suggestive of NMOSD, or for those in need of differential diagnosis from conditions with overlapping symptoms, this test offers a critical tool in the diagnostic process, aiding in the timely and effective management of the disorder.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

ANTI NMO NEUROMYELITIS OPTICA PANEL CSF Test

Price: 1200.0 AED

Sample Condition: 1 mL (0.5 mL min.) CSF in a sterile screw capped container. Ship refrigerated or frozen.

Report Delivery: Sample Tue / Fri by 9 am; Report Same day

Method: Cell based assay, IFA

Test Type: Disorders of Nervous System

Doctor: Neurologist

Test Department: IMMUNOPATHOLOGY

Pre Test Information: No special preparation required

Test Details

The anti-NMO (neuromyelitis optica) panel CSF test is a diagnostic test used to identify antibodies associated with neuromyelitis optica (NMO), also known as Devic’s disease. NMO is an autoimmune disorder that primarily affects the optic nerves and spinal cord.

The test involves analyzing the cerebrospinal fluid (CSF), which is the clear fluid that surrounds the brain and spinal cord, for the presence of specific antibodies called aquaporin-4 (AQP4) antibodies. These antibodies are found in about 70-80% of individuals with NMO and are believed to play a role in the development of the disease.

The anti-NMO panel CSF test is typically performed in individuals suspected of having NMO or those with unexplained optic neuritis or myelitis. It helps differentiate NMO from other similar conditions like multiple sclerosis (MS) and provides valuable information for accurate diagnosis and appropriate treatment.

During the test, a sample of CSF is collected through a lumbar puncture or spinal tap procedure. The CSF sample is then analyzed in a laboratory using various techniques, such as enzyme-linked immunosorbent assay (ELISA) or cell-based assays, to detect the presence of AQP4 antibodies.

A positive result indicating the presence of AQP4 antibodies suggests a higher likelihood of NMO. However, it is important to note that not all individuals with NMO will test positive for AQP4 antibodies, and some individuals without NMO may have these antibodies as well. Therefore, the test results should be interpreted in conjunction with the individual’s clinical symptoms and other diagnostic findings.

The anti-NMO panel CSF test plays a crucial role in the diagnosis and management of NMO, as it helps guide treatment decisions and monitor disease activity. Early detection and appropriate treatment can help prevent severe neurological damage and improve outcomes for individuals with NMO.

Test Name ANTI NMO NEUROMYELITIS OPTICA PANEL CSF Test
Components *Anti Aquaporin 4*Anti MOG
Price 1200.0 AED
Sample Condition 1 mL (0.5 mL min.) CSF in a sterile screw capped container. Ship refrigerated or frozen.
Report Delivery SampleTue / Fri by 9 am; Report Same day
Method Cell based assay, IFA
Test type Disorders of Nervous System
Doctor Neurologist
Test Department: IMMUNOPATHOLOGY
Pre Test Information No special preparation required
Test Details

The anti-NMO (neuromyelitis optica) panel CSF test is a diagnostic test used to identify antibodies associated with neuromyelitis optica (NMO), also known as Devic’s disease. NMO is an autoimmune disorder that primarily affects the optic nerves and spinal cord.

The test involves analyzing the cerebrospinal fluid (CSF), which is the clear fluid that surrounds the brain and spinal cord, for the presence of specific antibodies called aquaporin-4 (AQP4) antibodies. These antibodies are found in about 70-80% of individuals with NMO and are believed to play a role in the development of the disease.

The anti-NMO panel CSF test is typically performed in individuals suspected of having NMO or those with unexplained optic neuritis or myelitis. It helps differentiate NMO from other similar conditions like multiple sclerosis (MS) and provides valuable information for accurate diagnosis and appropriate treatment.

During the test, a sample of CSF is collected through a lumbar puncture or spinal tap procedure. The CSF sample is then analyzed in a laboratory using various techniques, such as enzyme-linked immunosorbent assay (ELISA) or cell-based assays, to detect the presence of AQP4 antibodies.

A positive result indicating the presence of AQP4 antibodies suggests a higher likelihood of NMO. However, it is important to note that not all individuals with NMO will test positive for AQP4 antibodies, and some individuals without NMO may have these antibodies as well. Therefore, the test results should be interpreted in conjunction with the individual’s clinical symptoms and other diagnostic findings.

The anti-NMO panel CSF test plays a crucial role in the diagnosis and management of NMO, as it helps guide treatment decisions and monitor disease activity. Early detection and appropriate treatment can help prevent severe neurological damage and improve outcomes for individuals with NMO.